Loading…
DexCom, Inc. is projected to rise to $88.10 by 2027, a +18% move from its current price of $74.85. DXCM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/29/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 31 | $73.23 | $74.86 | $76.53 | +0.01% |
| Aug 1 | $72.57 | $74.87 | $77.24 | +0.03% |
| Aug 2 | $72.08 | $74.88 | $77.80 | +0.04% |
| Aug 3 | $71.66 | $74.89 | $78.27 | +0.06% |
| Aug 4 | $71.30 | $74.90 | $78.69 | +0.07% |
| Aug 5 | $70.98 | $74.91 | $79.07 | +0.09% |
| Aug 6 | $70.68 | $74.92 | $79.42 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $70.68 | $74.92 | $79.42 | +0.10% |
| Week 2 | $69.06 | $75.00 | $81.45 | +0.20% |
| Week 3 | $67.86 | $75.07 | $83.05 | +0.30% |
| Week 4 | $66.88 | $75.15 | $84.44 | +0.40% |
| Week 5 | $66.03 | $75.22 | $85.70 | +0.50% |
| Week 6 | $65.28 | $75.30 | $86.86 | +0.60% |
| Week 7 | $64.60 | $75.38 | $87.95 | +0.70% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators.
The company was incorporated in 1999 and is headquartered in San Diego, California.
DexCom operates within the Healthcare sector and focuses on medical devices for CGM solutions used in diabetes management and metabolic health globally.
DexCom, Inc. (DXCM) is currently priced at $71.43 per share and has a market cap of $27.56B. It ranks 462 by market capitalization.
The 30-day technical picture remains constructive with bullish sentiment, RSI14 at 50, and moving averages near the current price: SMA50 at $71.28 and SMA200 at $67.46.
Near-term support sits at $67.35 and resistance at $78.19. The 30-day price range spans from $61.19 to $83.38, and annualized volatility is 40%.
Forecasts show a multi-year upside path, with the average forecast price rising from $71.43 in 2026 to $117.95 in 2030 and up to $565.09 by 2050, while max values reach as high as $989.66. ROI figures rise from 0% in 2026 to 65.1% in 2030 and 691.1% by 2050, indicating a strong long-term upside potential.
A major floor 23.1% below — a decisive break under it would weaken the trend.
The nearest floor, 10.0% below — buyers have tended to step in here.
The nearest ceiling, 4.2% above — a clean break opens room to run.
A major ceiling 12.3% above — clearing it would confirm fresh momentum.
Key DXCM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DXCM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $72.33 | Buy | $73.44 | Buy |
| MA 10 | $73.95 | Buy | $73.48 | Buy |
| MA 20 | $73.27 | Buy | $73.21 | Buy |
| MA 50 | $72.34 | Buy | $71.53 | Buy |
| MA 100 | $67.88 | Buy | $69.97 | Buy |
| MA 200 | $67.57 | Buy | $70.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.75 | Neutral |
| Stoch RSI (14) | 54.98 | Neutral |
| CCI (20) | 51.69 | Neutral |
| Williams %R (14) | -41.73 | Info |
| MACD (12,26,9) | -0.23 | Sell |
| ROC (12) | -0.15 | Sell |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 58.27 | Neutral |
| TRIX (15) | 0.15 | Buy |
| Awesome (5,34) | -0.51 | Sell |
| Ultimate (7,14,28) | 45.84 | Neutral |
| Momentum (10) | 0.73 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 71.96 | Buy |
| ADX (14) | 12.77 | Neutral |
| ATR (14) | 1.62 | Info |
The 30-day technical picture is bullish, with sentiment labeled as BULLISH and an RSI14 of 50, indicating balanced momentum.
The stock trades above the SMA50 of $71.28 and above the SMA200 of $67.46, suggesting upside pressure remains when price moves toward near-term resistance.
Key support and resistance levels are $67.35 and $78.19, respectively. The 30-day price range runs from $61.19 to $83.38, and annualized volatility sits at 40%, signaling notable price swings over the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $57.56 | $74.85 | $98.51 | 0% | Neutral | |
| $71.48 | $88.10 | $114.01 | +18% | Neutral | |
| $75.90 | $95.66 | $127.70 | +28% | Bullish | |
| $81.85 | $105.06 | $143.72 | +40% | Bullish | |
| $96.08 | $125.32 | $174.99 | +67% | Bullish | |
| $111.23 | $147.21 | $209.28 | +97% | Bullish | |
| $122.72 | $164.63 | $237.84 | +120% | Bullish | |
| $130.35 | $177.08 | $259.60 | +137% | Bullish | |
| $136.14 | $187.16 | $278.12 | +150% | Bullish | |
| $145.42 | $202.21 | $304.28 | +170% | Bullish | |
| $214.29 | $313.57 | $497.49 | +319% | Bullish | |
| $385.43 | $614.54 | $1,053.95 | +721% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $57.56 | $74.85 | $87.74 | +0.00% |
| August 2026 | $65.31 | $76.38 | $91.21 | +2.05% |
| September 2026 | $64.42 | $75.83 | $91.52 | -0.72% |
| October 2026 | $64.37 | $76.18 | $92.73 | +0.46% |
| November 2026 | $66.25 | $78.74 | $96.51 | +3.36% |
| December 2026 | $66.93 | $79.88 | $98.51 | +1.44% |
Click any year to see its month-by-month DXCM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DXCM to range from $57.56 to $98.51 through 2026. The $74.85 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The DXCM price prediction for 2027 points to an average of $88.10 (low $71.48, high $114.01) — a potential gain of +18% on today's $74.85. Price action looks broadly range-bound.
In 2028, DXCM is projected to trade between $75.90 and $127.70, averaging $95.66 — a potential gain of +28% from today's $74.85. That is up +9% on the projected 2027 average. Buyers look set to stay in control over this stretch.
DexCom, Inc.'s 2029 outlook centres on $105.06, within a $81.85 to $143.72 range. That is up +10% on the projected 2028 average. That marks a +40% change versus current levels. Momentum favours further upside here.
By 2030, DXCM could reach as high as $174.99, with a base case around $125.32 and support toward $96.08 — roughly +67% from $74.85. Buyers look set to stay in control over this stretch.
Expect DXCM to range from $111.23 to $209.28 through 2031. The $147.21 average target implies a +97% move from current prices. That is up +17% on the projected 2030 average. Momentum favours further upside here.
The DXCM price prediction for 2032 points to an average of $164.63 (low $122.72, high $237.84) — a potential gain of +120% on today's $74.85. Buyers look set to stay in control over this stretch.
In 2033, DXCM is projected to trade between $130.35 and $259.60, averaging $177.08 — a potential gain of +137% from today's $74.85. That is up +8% on the projected 2032 average. Momentum favours further upside here.
DexCom, Inc.'s 2034 outlook centres on $187.16, within a $136.14 to $278.12 range. That is up +6% on the projected 2033 average. That marks a +150% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, DXCM could reach as high as $304.28, with a base case around $202.21 and support toward $145.42 — roughly +170% from $74.85. Momentum favours further upside here.
Expect DXCM to range from $214.29 to $497.49 through 2040. The $313.57 average target implies a +319% move from current prices. That is up +55% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The DXCM price prediction for 2050 points to an average of $614.54 (low $385.43, high $1,053.95) — a potential gain of +721% on today's $74.85. Momentum favours further upside here.
Investing $1,000 in DXCM today (≈ 13.360053 DXCM) could be worth
$8,210.33
+$7,210.33 (+721%) by 2050 · US Dollar
Based on the average projected DXCM price of $614.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DXCMwould be worth at today's price.
$1,000 invested in DXCM on Jul 28, 2025 (≈ 11.169441 DXCM) would be worth
$836.03
-$163.97 (-16.4%) today · 0.84× · US Dollar
Based on a DXCM entry price of $89.53 vs. today's $74.85.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $74.75 | $1,001.34 | +0.1% |
| 1 month ago | $69.98 | $1,069.59 | +7.0% |
| 3 months ago | $57.56 | $1,300.38 | +30.0% |
| 6 months ago | $74 | $1,011.49 | +1.1% |
| 1 year ago | $89.53 | $836.03 | -16.4% |
| All time (5.0y) ago | $127.84 | $585.51 | -41.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DXCM forecast.
Our base-case forecast reaches $150.00 around 2032.
Implied market cap at $150.00: $57.88B
The multi-year forecast lays out a clear bullish trajectory, with the 2030 average price at $117.95 and ROI of 65.1%, the 2040 average at $291.78 with ROI of 308.5%, and the 2050 average at $565.09 with ROI of 691.1%. These figures point to substantial upside potential over the coming decades, recognizing that longer-horizon results are not guaranteed.
Between 2031 and 2035, the forecast shows continued growth in average prices, reaching $139.17 (2031), $153.99 (2032), $166.42 (2033), $175.50 (2034), and $186.95 (2035), with corresponding increases in max values and solid bullish sentiment.
The forecast underscores bullish momentum into the 2040s and beyond, with 2040 expected to average $291.78 and 2050 to average $565.09, accompanied by rising max targets. While these projections illustrate a strong long-term path, they reflect estimates and are subject to uncertainty and market volatility, including the 40% annualized volatility observed in the near term.
Tap a question to reveal the answer.
The 2030 forecast shows min $89.61, avg $117.95, max $166.56 with ROI 65.1% and sentiment BULLISH.
Long-term forecasts show a bullish trajectory with average prices rising to $565.09 by 2050 and ROI 691.1%, though 2026 is neutral and outcomes depend on future conditions. The near term also shows a range of possibilities given volatility.
Yes. The 2032 forecast lists an average of $153.99 and a max of $225.39, with 2033 at $166.42 average and higher max values, indicating the potential to surpass $150 in the forecast horizon.
Current price is $71.43. Market cap is $27.56B. It ranks 462.
The 30-day range is $61.19 to $83.38. RSI14 is 50. SMA50 is $71.28 and SMA200 is $67.46. Support is $67.35 and resistance is $78.19, with bullish sentiment.
DexCom, Inc. Community Discussion
0Share your DexCom, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.